- Rightside Offers
- Posts
- 12-24-24 RSO FuturHealth CPC News AM
12-24-24 RSO FuturHealth CPC News AM
Today’s News!
Good morning, patriots, and Merry Christmas Eve! As we prepare to celebrate, today’s stories include a fascinating archaeological find tied to Sant
Top News
Santa Claus Sarcophagus Discovered During Excavation Project
In a discovery fit for the season, archaeologists believe they’ve uncovered the sarcophagus of Saint Nicholas—the real-life inspiration for Santa Claus. Found during an excavation in Turkey, the ancient relic is sparking excitement among historians and Christmas enthusiasts alike.
The discovery offers a deeper connection to the legend of Santa Claus and highlights the enduring impact of Saint Nicholas on global holiday traditions. Could this be the ultimate Christmas gift for history buffs?
LNG and Climate: Trump’s Role in Shaping the Future
As discussions around LNG (liquefied natural gas) and climate policies heat up, the Trump administration’s legacy is becoming a central talking point. Advocates argue that LNG remains a cleaner alternative to coal, while critics claim it delays necessary shifts to renewable energy.
With the global demand for natural gas surging, this debate is far from over. The intersection of energy security and environmental stewardship will likely dominate 2025.
Economic Watch
Holiday spending continues to reach record highs, with retailers reporting stronger-than-expected sales. This festive season is providing a much-needed economic boost.
Cartoon of the Day
Advertisement
Weight Loss Made Easy
92% of users achieved lasting results with semaglutide!
No insurance needed
Users say this is more effective than anything they’ve ever tried
This is an advertisement.
You are receiving this message because you opted-in to receive emails from a third-party publisher. This email was delivered by a third-party, on behalf of FuturCo Health Technologies, Inc. Copyright © FuturCo Health Technologies, Inc. All Rights Reserved. 3902 La Cresta Drive San Diego, CA 92107.
*Based on the average weight loss in three 68-week clinical trials of patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, along with a reduced- calorie diet and increased physical activity. See details. Results may vary based on starting weight and program adherence. Medication prescriptions are at the discretion of medical providers and may not be suitable for everyone. Consult a healthcare professional before starting any weight loss program.
Zepbound is FDA-approved for type 2 diabetes treatment, but may be prescribed for weight loss. The trademarks, service marks, trade names (Wegovy®, Ozempic®), and products displayed on this Internet site are protected and belong to their respetive owners.
Quote of the Day
"Christmas is not a date. It is a state of mind."
– Mary Ellen Chase
This email has ads brought to you by our sponsors.